CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Back to HPHA.DE

124-Iodine-cG250 (124I-cG250)

Phase 3
Heidelberg Pharma AG (HPHA.DE)

Phase 3

Development Phase

0

Upcoming Catalysts

0

Historical Events

0

Regulatory Approvals

No Catalysts Found

No catalyst events have been recorded for this drug yet.

Competitive Landscape

0 competitors in Renal Cell Carcinoma

View Full Landscape
Drug Information

Target Indication

Renal Cell Carcinoma

Clinical Trial

NCT00606632

Last updated: 6/28/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Drug Science
Mechanism of action & safety profile
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts

Weekly digest every Monday. Unsubscribe anytime.